TISIDB

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm. Nucleus. Cytoplasm, cytoskeleton. Cell projection, lamellipodium. Note=Predominantly cytoplasmic but a small proportion colocalizes with SSX2 in the nucleus. Activation of protein kinase C results in redistribution to the periphery of lamellipodia. In the cytoskeleton, localizes to cortical actin.
Domain	PF06428 GDP/GTP exchange factor Sec2p
Function	Guanine nucleotide exchange factor (GEF) which may activate RAB8A and RAB8B. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form. Mediates the release of GDP from RAB8A and RAB8B but not from RAB3A or RAB5. Modulates actin organization and promotes polarized transport of RAB8A-specific vesicles to the cell surface. Together with RAB11A, RAB8A, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis.

> Gene Ontology [ TOP ]
Biological Process	GO:0006612 protein targeting to membrane GO:0072657 protein localization to membrane GO:0090150 establishment of protein localization to membrane
Molecular Function	GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0017112 Rab guanyl-nucleotide exchange factor activity
Cellular Component	GO:0030027 lamellipodium GO:0031252 cell leading edge

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5620912: Anchoring of the basal body to the plasma membrane R-HSA-5620922: BBSome-mediated cargo-targeting to cilium R-HSA-5620920: Cargo trafficking to the periciliary membrane R-HSA-5617833: Cilium Assembly R-HSA-199991: Membrane Trafficking R-HSA-1852241: Organelle biogenesis and maintenance R-HSA-8876198: RAB GEFs exchange GTP for GDP on RABs R-HSA-5653656: Vesicle-mediated transport R-HSA-5620916: VxPx cargo-targeting to cilium

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-5620922: BBSome-mediated cargo-targeting to cilium
R-HSA-5620920: Cargo trafficking to the periciliary membrane
R-HSA-5617833: Cilium Assembly
R-HSA-199991: Membrane Trafficking
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-8876198: RAB GEFs exchange GTP for GDP on RABs
R-HSA-5653656: Vesicle-mediated transport
R-HSA-5620916: VxPx cargo-targeting to cilium

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between RAB3IP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of RAB3IP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of RAB3IP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.799	0.0088
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.936	0.108
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.699	0.157
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.5	0.223
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.604	0.693
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.372	0.849
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.235	0.636
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.041	0.291
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.538	0.58
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.019	0.989
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.226	0.914
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.472	0.00163

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of RAB3IP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	6.8	-6.8	0.32
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	8.5	-8.5	0.32
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RAB3IP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RAB3IP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RAB3IP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RAB3IP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of RAB3IP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between RAB3IP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	RAB3IP
Name	RAB3A interacting protein
Aliases	RABIN3; FLJ22548; RABIN8; SSX2 interacting protein; rab3A-interacting protein; rabin-3; Rab-3A-interacting p ......
Chromosomal Location	12q15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting RAB3IP collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse RAB3IP